Verana Health Enhances Data and AI for Ophthalmology Research
Verana Health introduced new data and software solutions to advance ophthalmology research and treatment optimization. The company unveiled AI Agents and datasets leveraging data from over 90 million de-identified patients.
Digital health company Verana Health has announced significant enhancements to its data and software solutions, aimed at improving real-world data insights and expediting treatment options in ophthalmology.
The company unveiled its new AI Agents and datasets, utilizing data from over 90 million de-identified patients, in advance of the American Academy of Ophthalmology's (AAO) annual meeting.
The new tools include AI agents and expanded datasets designed to accelerate clinical trial prescreening and provide deeper real-world evidence for various eye conditions, including retinal vein occlusion and Stargardt disease.
Verana Health CEO Sujay Jadhav stated the company is dedicated to providing technology and data-driven solutions for advancing ophthalmic research and patient care. The new features are intended to equip clinicians and life science companies with precise tools to accelerate discoveries and elevate patient outcomes.